Developing vaccines to protect against Ebola and related viruses
Advanced Development of Vaccines for Filoviruses
This study is working on a new vaccine that could help protect people from several serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and distribute, so it can be tested in the future to keep everyone safer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auro Vaccines LLC NIH-funded |
| Lab location | 1 site (East Windsor, United States) |
| Project ID | NIH-11250796 on NIH RePORTER |
What this research studies
This research focuses on creating a multivalent vaccine that aims to protect against several dangerous viruses, including Ebola, Marburg, and Lassa Fever. The approach involves formulating a stable vaccine that can be lyophilized for easier storage and distribution. The research will also include the preparation and submission of an Investigational New Drug (IND) application to facilitate clinical testing of the vaccine candidates. Patients may benefit from this research as it seeks to provide broader protection against multiple viral threats.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit would include individuals at high risk of exposure to filoviruses, such as healthcare workers and residents in endemic regions.
Not a fit: Patients who are not at risk of exposure to filoviruses or those who have already been vaccinated against these viruses may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that protects against multiple deadly viruses, potentially saving lives during outbreaks.
How similar studies have performed: Other research has shown promise in developing vaccines for filoviruses, indicating that this approach has potential based on previous successes.
Where this research is happening
East Windsor, United States
- Auro Vaccines LLC — East Windsor, United States (Active)
Researchers
- Principal investigator: Eldridge, John — Auro Vaccines LLC
- Study coordinator: Eldridge, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.